新华制药(000756) - 2024 Q3 - 季度财报

Financial Performance - Revenue for Q3 2024 reached ¥2,001,684,773.51, an increase of 9.67% year-over-year[2] - Net profit attributable to shareholders decreased by 35.60% to ¥78,675,532.99 in Q3 2024[2] - Basic earnings per share fell by 38.89% to ¥0.11, while diluted earnings per share decreased by 33.33% to ¥0.12[2] - Total operating revenue for Q3 2024 reached CNY 6,734,166,240.75, an increase of 3.64% compared to CNY 6,497,534,830.57 in the same period last year[16] - The net profit for Q3 2024 was CNY 355,449,271.22, a decrease of 11.2% compared to CNY 400,289,758.47 in Q3 2023[17] - Operating profit for the quarter was CNY 398,270,352.14, down 10.8% from CNY 446,870,220.76 in the same period last year[17] - The company’s total profit for the quarter was CNY 392,917,627.43, down from CNY 446,476,766.85 in Q3 2023, representing a decline of 12%[17] Cash Flow and Liquidity - Operating cash flow for the year-to-date increased significantly by 233.45% to ¥254,240,659.40[2] - The company reported a net cash flow from operating activities of ¥254,240,659.40 for the year-to-date, a significant increase compared to the previous year[6] - As of September 30, 2024, the company's cash and cash equivalents amounted to ¥1,158,318,911.44, an increase from ¥918,334,462.29 at the beginning of the period, reflecting a growth of approximately 26.1%[13] - The net increase in cash and cash equivalents was CNY 261.30 million, compared to a decrease of CNY 309.04 million in the same period last year[19] - Cash used for debt repayment amounted to CNY 598.69 million, an increase from CNY 472.56 million in the previous period[19] - Cash distributed as dividends, profits, or interest payments totaled CNY 224.28 million, up from CNY 166.52 million year-over-year[19] - Net cash flow from financing activities was CNY 135.15 million, a significant improvement from a negative CNY 207.93 million in the prior year[19] Assets and Liabilities - Total assets as of the end of Q3 2024 were ¥8,824,372,920.30, reflecting a 6.50% increase from the end of the previous year[2] - Current liabilities rose to CNY 2,703,569,750.62, up from CNY 2,486,000,478.39, representing an increase of 8.75%[15] - The company’s total liabilities reached CNY 3,728,365,398.25, compared to CNY 3,510,413,044.14, an increase of 6.22%[15] - Shareholders' equity attributable to shareholders increased by 6.99% to ¥4,871,406,971.82[2] - The total equity attributable to shareholders reached CNY 4,871,406,971.82, compared to CNY 4,553,103,869.56, reflecting an increase of 6.97%[15] Operational Metrics - Total operating costs amounted to CNY 6,337,089,365.67, up from CNY 6,039,257,829.40, reflecting a year-on-year increase of 4.92%[16] - Research and development expenses for the quarter were CNY 326,669,940.69, slightly down from CNY 341,281,879.49, indicating a decrease of 4.27%[16] - The company reported a decrease in sales expenses to CNY 504,223,794.96 from CNY 643,446,889.77, a reduction of 21.63%[16] Market and Strategic Developments - The decline in net profit was primarily due to price reductions on certain products to enhance market share amid intense competition[6] - The company has not disclosed any new product developments or technological advancements in this report[12] - There are no significant updates regarding market expansion or mergers and acquisitions mentioned in the report[12] - The report does not provide specific future outlook or performance guidance for the upcoming quarters[12] Shareholder Information - The total number of ordinary shareholders at the end of the reporting period was 82,944[7] - The company has not reported any changes in major shareholders or significant shareholder activities related to margin trading[9] Accounting and Compliance - The company has implemented changes in accounting policies effective January 1, 2024, in accordance with the Ministry of Finance's new guidelines, with no significant impact on the consolidated financial statements[12] - The company has not yet adopted the new accounting standards for the current year[19] - The third quarter report has not been audited[19]